Clinical Trials on Ventilator-acquired Pneumonia in Japan

Total 109 results

Shionogi

Completed

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens (APEKS-NP)

Hospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)

Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
Osaka General Medical Center
Wakayama Medical University; Nagasaki University; University of the Ryukyus; Kansai... and other collaborators

Completed

GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial

Ventilator Associated Pneumonia

Japan
Meiji Seika Pharma Co., Ltd.

Recruiting

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (Integral-2)

Acute Pyelonephritis | Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection | Ventilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia

Japan
Pfizer

Completed

A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia

Ventilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)

Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
Okayama Research Investigator Organizing Network

Unknown

Intubation and Extubation Over 48 Hours Mechanical Ventilation (INDEX48)

Critical Illness | Pneumonia, Ventilator-Associated

Japan
Shionogi

Completed

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens (CREDIBLE - CR)

Sepsis | Bloodstream Infections (BSI) | Hospital Acquired Pneumonia (HAP) | Complicated Urinary Tract Infection (cUTI) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)

United States, Brazil, Croatia, France, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United Kingdom
Ono Pharmaceutical Co. Ltd

Completed

Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

Community-acquired Pneumonia

Japan
Pfizer

Completed

Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)

Streptococcus Pneumoniae | Pneumococcal Vaccine

Japan
Osaka University

Completed

Predictors Of Successful Extubation in Critically Ill Patients: Multicentre Observational Study (POSE)

Intubation | Critical Care | Extubation | Mechanical Ventilation | Weaning | Liberation From Mechanical Ventilation

Japan
Pfizer

Completed

A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults

Pneumonia, Community-Acquired

Japan
Pfizer

Completed

The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

Community Acquired Pneumonia (CAP)

Japan
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
Hamamatsu University

Completed

The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia

Chronic Disease | Eosinophilic Pneumonia

Japan
Melinta Therapeutics, Inc.

Completed

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia (SOLITAIRE-IV)

Community-acquired Bacterial Pneumonia

Spain, United States, Philippines, Taiwan, Canada, Germany, Poland, Russian Federation, Argentina, Bulgaria, South Africa, Slovenia, Serbia, Colombia, Hungary, Netherlands, Slovakia, Ukraine, Peru, Latvia, Guatemala, Romania, Chile, G... and more
Nagoya University

Unknown

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Acquired Aplastic Anemia.

Japan
AstraZeneca

Completed

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan (Evusheld DBR)

COVID-19

Japan
Pfizer

Completed

Special Investigation of COMIRNATY in the Population With Underlying Diseases

COVID-19

Japan
AnGes, Inc.

Completed

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

COVID-19

Japan
AnGes, Inc.
Japan Agency for Medical Research and Development

Completed

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

COVID-19

Japan
Pfizer

Completed

Drug Use Investigation of COMIRNATY Intramuscular Injection

COVID-19

Japan
Genova Inc.
Tokyo Shinagawa Hospital

Recruiting

Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

Covid19

Japan
Pfizer

Active, not recruiting

Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

COVID-19 | SARS-CoV-2

Japan
ModernaTX, Inc.

Completed

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Coronavirus Disease (COVID-19)

Japan
ModernaTX, Inc.

Completed

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

SARS-CoV-2

Japan
ModernaTX, Inc.

Completed

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

SARS-CoV-2

Japan
Takeda

Withdrawn

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Coronavirus Disease (COVID-19)

Japan
Pfizer

Completed

A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

SARS-CoV-2 Infection

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Covid19

Japan
Kitasato University

Active, not recruiting

Study in COvid-19 Patients With iveRmectin (CORVETTE-01)

Covid19

Japan
Tohoku University

Completed

Vitamin D Supplementation Prevents Elderly Pneumonia

Bacterial Pneumonia

Japan
ModernaTX, Inc.

Completed

Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

SARS-CoV-2

Japan
Novo Nordisk A/S

Completed

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

Healthy | Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary Bypass

Japan
Bristol-Myers Squibb

Completed

A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan

COVID-19

Japan
University of Jazan

Completed

Hallux Valgus Conservative Treatment (RCT)

Hallux Valgus

Saudi Arabia
UMC Utrecht
National University Hospital, Singapore; Berry Consultants; University of Pittsburgh... and other collaborators

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)

Community-acquired Pneumonia, Influenza, COVID-19

United Kingdom, United States, Canada, Australia, Netherlands, Croatia, Germany, Belgium, New Zealand, Ireland, Spain, Japan, Hungary, Colombia, India, Nepal, Pakistan, Portugal, Romania, Saudi Arabia
Sanofi

Completed

Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia

Pneumonia

Japan
Humanity & Health Medical Group Limited
Tokyo University; Nihon University School of Medicine

Recruiting

Liver Injury After COVID-19 Vaccination

Subjects After COVID-19 Vaccination

Japan, Hong Kong
Takeda

Completed

A Study of TAK-919 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
Takeda

Completed

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Coronavirus Disease (COVID-19)

Japan
BioNTech SE
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

COVID-19 | SARS-CoV-2 Infection

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2

Japan
Rohto Pharmaceutical Co., Ltd.

Completed

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

SARS-CoV-2 Infection( COVID-19 )

Japan
Yubari Kibounomori
Health Research Foundation

Completed

Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist

Pneumonia

Japan
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
Novo Nordisk A/S

Completed

Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Japan
Astellas Pharma Inc

Completed

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Japan
AstraZeneca

Terminated

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Prevention of Infectious Disease Caused by SARS-CoV-2

Japan
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
North East Japan Study Group
Boehringer Ingelheim

Active, not recruiting

Japanese Idiopathic Interstitial Pneumonias Registry (JIPS)

Idiopathic Interstitial Pneumonia

Japan
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan

Clinical Trials on Ventilator-acquired Pneumonia in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations